Asthma Clinical Trials

Find Asthma Clinical Trials Near You

A Randomized, Double-blind, Placebo-controlled Phase Ib/II Study to Evaluate the Efficacy and Safety of HB0056 in Adult Participants With Moderate to Severe Asthma

Status: Recruiting
Location: See all (2) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 1/Phase 2
SUMMARY

The goal of this clinical trial is to learn if drug HB0056 works to treat severe asthma in adults. It will also learn about the safety of drugHB0056. The main questions it aims to answer are: Does drug HB0056 lower the number of times participants need to use a rescue inhaler? What medical problems do participants have when taking drug HB0056? Researchers will compare drug HB0056 to a placebo to see if drug HB0056 works to treat severe asthma. Participants will: Take drug HB0056 or a placebo Q2W. Keep a diary of their symptoms and the number of times they use a rescue inhaler

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Male or female subjects aged 18-75 years (inclusive) \[as of the date of signing the informed consent form (ICF)\];

• Body weight≥ 40 KG and body mass index is between 18-40 kg/m2;

• Diagnosis of asthma with a medical history of at least 1 year;

• Those who have received a moderate-to-high dose of ICS (≥ 250 μg fluticasone propionate dry powder formulation equivalent total daily dose) for ≥ 3 consecutive months prior to screening, combined with at least one asthma control drug that has been maintained a stable treatment regimen and dose for ≥ 1 month prior to screening;

• At least 1 asthma exacerbation within 12 months prior to screening;

• 40% ≤ FEV1 \< 80% of predicted normal value pre-bronchodilator at screening;

• There is a record of reversibility test result of FEV1 ≥ 12% and ≥ 200 mL within 12 months prior to randomization, or the reversibility test result meets FEV1 ≥ 12% and ≥ 200 mL at screening;

• ACQ-6 score ≥1.5 prior to randomization;

• No birth planning and voluntarily use effective contraception throughout the study until 6 months after the last dose;

Locations
Other Locations
China
China-Japan Friendship Hospital
RECRUITING
Beijing
China-Japan Friendship Hospital
RECRUITING
Beijing
Contact Information
Primary
Jingjing Wang
jingjing.wang@huaota.com
86-21-5132 0051
Time Frame
Start Date: 2025-08-21
Estimated Completion Date: 2028-08-01
Participants
Target number of participants: 160
Treatments
Active_comparator: HB0056
HB0056 SC injection every 2/4 weeks .
Placebo_comparator: Placebo
Placebo
Related Therapeutic Areas
Sponsors
Leads: Shanghai Huaota Biopharmaceutical Co., Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials